How Much Do RYZUMVI® Eye Drops Cost?

Published on February 27, 2026 | Prices Last Reviewed for Freshness: March 2026
Written by Alec Pow - Economic & Pricing Investigator | Medical Review by Sarah Nguyen, MD

RYZUMVI (phentolamine ophthalmic solution) 0.75% prescription eye drops are usually best understood from the clinic supply chain (a box of single-patient-use vials that must be handled like a refrigerated pharmaceutical) and then translated into what a patient pays either as an in-office “dilation reversal” add-on or as a pharmacy claim depending on how the practice dispenses it.

TLDR: A clinic distributor listing posts RYZUMVI at $290 per 30-vial box (about $9.67 per single-use vial before refrigerated freight), and cold-ship programs can add separate expedited shipping fees. Your personal out-of-pocket is most often either a visit add-on when the clinic supplies a vial, or a pharmacy receipt if you fill a prescription and run it through insurance or cash pricing.

RYZUMVI is used at the end of an eye exam or procedure after pharmacologic pupil dilation (for example with phenylephrine or tropicamide), so it behaves economically like a visit-linked supply rather than a monthly refill. That single-visit orientation is why two people can both “use RYZUMVI” and still report very different prices: one is paying an office fee for a dose administered on-site, while another is paying a pharmacy for a prescription fill that gets processed under a drug benefit.

Important numbers

The cleanest public “anchor” numbers for RYZUMVI typically come from clinic-facing sources rather than patient retail shelves, because many practices order it as inventory and administer it on-site. One distributor listing posts a $290 price for a box and describes it as a clinic purchase item, which is a helpful starting point when you’re trying to understand why an office add-on charge might exist at all.

That same box-level anchor matters because RYZUMVI is commonly discussed as a box-and-vial product rather than a multi-dose bottle you take home and stretch over time. When you see a per-visit fee at the front desk, the office is effectively converting its acquisition cost (product + refrigerated freight + handling) into a patient-facing number that fits an appointment workflow.

Shipping is the second big variable. Many refrigerated pharmaceuticals ship separately using expedited service, and cold-ship programs often list separate shipping fees and constraints that can change the delivered total even if the posted box price stays the same.

If a practice orders small quantities or needs faster delivery, the shipping component can become meaningful relative to a single box, which then influences how the office sets a per-visit add-on amount. In short: think “box price + cold shipping + office policy,” not “one universal retail price.” See the posted box anchor on the RYZUMVI distributor product listing.

What you’re actually buying

RYZUMVI is packaged and used in a way that makes cost-per-use math unusually straightforward compared with many eye drops. Instead of a multi-dose bottle, the product is supplied as single-patient-use vials and intended for administration after dilation during an ophthalmic visit.

In practical terms, that means the “unit” a clinic consumes is typically one vial for one patient encounter, not a bottle that can be used across many days or shared across multiple patients. That packaging drives the economics: clinics buy boxes, store and handle them as inventory, and then decide whether to charge patients a separate fee when a vial is used.

For patients, the packaging answers two common questions. First, it explains why “price per dose” can be more relevant than “price per month.” Second, it explains why many offices treat RYZUMVI like an opt-in convenience service (dilation reversal) instead of something automatically included with dilation.

Even if your clinic never shows you the underlying box cost, it is still operating under the constraints of single-use inventory, refrigerated handling, and the administrative friction of ordering and stocking. The easiest public confirmation of the “30 vials per box” packaging detail appears on a clinic-oriented listing such as the Keeler USA RYZUMVI packaging page.

Clinic purchasing realities

Cold-shipping is one of the biggest reasons RYZUMVI can feel “expensive” in real life even when the base box anchor seems manageable on paper. Refrigerated products often ship in insulated packaging with cold packs, and distributors may ship them separately from ambient products using expedited services. T

hat can add a fixed cost per order, which becomes especially noticeable when a practice orders only one box at a time. Those fixed logistics costs can also change reorder behavior: some practices will order less frequently to reduce per-order shipping overhead, while others prioritize always having product available for patient requests.

Cold-ship program terms can add other friction that affects how clinics price the service. Limited ship days can force practices to plan ahead, and non-return rules mean that ordering mistakes or unused inventory may not be reversible. Even without spoilage, any product that sits in inventory has an opportunity cost and a compliance burden (storage, monitoring, handling).

When you’re offered RYZUMVI as a same-day option at checkout, you’re seeing the downstream result of those upstream constraints. A clear public example of these logistics (including fee schedule structure and policy language) is shown on the Sigma cold-ship products and fee terms page.

Retail pharmacy vs in-office dosing

There isn’t one single “RYZUMVI price” because the drug can be paid for through different channels. In-office dosing usually means the clinic purchased the product, administered it after dilation, and then charged you a visit add-on amount (which may or may not be processed through insurance depending on the office’s billing setup).

In that path, you’re buying a service experience: convenience, timing, and reduced dilation duration, bundled into a clinic-controlled workflow. The clinic is also absorbing the logistics of ordering, cold storage, and managing inventory risk.

By contrast, a pharmacy pathway usually means you receive a prescription and fill it like a drug claim. That introduces all the usual pharmacy variables: plan tier placement, deductible stage, formulary requirements, and whether a prior authorization is needed.

This can be a poor fit for last-minute decisions, because the value of RYZUMVI is tightly linked to the timing of a dilated visit. Some patients still prefer the pharmacy route if coverage is favorable or if they want the transaction to be processed under their drug benefit rather than handled as an office add-on. Coverage framing and plan mechanics are summarized in consumer terms on the GoodRx Medicare coverage page for RYZUMVI (useful even if you’re not on Medicare because the plan concepts are similar).

Insurance friction

For episodic drugs used around a specific appointment, the biggest insurance “cost” can be timing friction rather than dollars. If a payer requires prior authorization (PA), the patient may not be able to get the medication approved and filled in time for the scheduled dilated exam.

That can push decision-making back onto the clinic: either the office provides an in-house option (and bills accordingly) or the patient waits for dilation to wear off naturally. In other words, PA can change the set of real options available on exam day.

If you’re comparing what RYZUMVI might add to a visit, it can help to benchmark it against other eye-care spending categories. For example, our guide to Vizz eye drops cost shows how OTC drop pricing behaves when you’re buying a bottle at retail, while the SMILE Pro eye surgery cost breakdown illustrates how clinics bundle supplies, surgeon fees, and facility charges into procedure-style pricing. And if you want a “drug benefit” comparison for how insurance, tiers, and deductibles can swing out-of-pocket on a branded medication, see our overview of Rybelsus cost for a practical sense of why the same prescription can land at very different totals depending on the plan and timing.

PA also affects patient expectations. Many people assume that if a drug is FDA-approved and available, insurance will simply assign a copay. But branded ophthalmic products can be subject to utilization management, and the criteria can vary by payer.

Even when the out-of-pocket would ultimately be reasonable, the paperwork and delay can make the pharmacy route impractical for a one-time exam-related use case. A concrete public example of how a payer gates access is the Minnesota DHS RYZUMVI prior authorization criteria page. The details on that page won’t match every plan, but it illustrates the kind of hurdles that can exist.

What an eye office may charge

Because office pricing varies, you won’t reliably find a national, patient-facing “posted price” for a RYZUMVI dose administered in clinic. Instead, you’ll typically get a quote at checkout that reflects the practice’s own costs and policies. The most defensible way to sanity-check that quote is to break it into components:

(1) the supply component (a single-use vial drawn from a box),

(2) the logistics component (cold-ship shipping and storage burden), and

(3) the service component (administration workflow, documentation, and the practice’s margin for offering the option consistently).

Using the public box anchor, you can approximate the supply-only floor. With a $290 box and 30 vials, the box-level math implies about $9.67 per vial before shipping. Add cold-ship overhead and you can see how a practice’s per-dose “true cost” could rise above $10 even before any service markup.

Then remember: a clinic add-on price is not just “drug acquisition,” it’s also a same-day convenience offering that the clinic must keep in stock, manage, and explain to patients. If your quote seems high, the most useful questions are operational: “Is this billed as a clinic supply or a pharmacy prescription?” and “Does the price include the dose administered today?” Those answers tell you which pay path you’re in and what you’re actually paying for.

Worked example

Here’s a clean conversion using only publicly posted anchor numbers to illustrate how clinics translate inventory into a per-use cost. Start with the posted $290 box anchor and the packaging detail of 30 vials per box. Divide $290 by 30 and you get $9.67 per vial before shipping. That is not what a patient necessarily pays; it’s a supply-side anchor for the product component only.

Next, layer in shipping. Cold-ship programs often add an order-level fee that doesn’t scale linearly with the number of vials used for any single patient. If you assume a small-order cold-ship fee example of $15, then the delivered cost for that one-box order becomes $305.

Divide $305 by 30 vials and you get $10.17 per vial delivered. If the office uses roughly one vial per dilated patient encounter (consistent with the single-use intent), then $10.17 becomes a reasonable “floor” for the acquisition component of an in-office add-on charge, before any clinic service markup. This example also shows why higher expedited shipping options can raise the delivered per-vial cost if order volume is low. The key takeaway is not that every clinic will charge $10 or $20; it’s that the clinic’s quote is often rooted in box economics plus refrigerated logistics, not a retail shelf tag.

Quick context

The product’s approval messaging emphasizes its role in reversing pharmacologically-induced mydriasis, which aligns closely with how eye-care practices structure visits and patient flow. That naturally encourages clinic stocking and point-of-care use: it’s easier to offer a reversal option when the patient is already in the chair and the timing is predictable.

Launch and commercialization notes also support the “clinic workflow” framing. If distribution and commercialization are oriented toward eye-care practices and their purchasing channels, it’s unsurprising that some patients experience RYZUMVI as a billed add-on service rather than a typical consumer prescription journey. For those who want to verify the timeline and positioning, see the Viatris/Ocuphire FDA approval announcement and the later U.S. commercial launch release. This doesn’t set a price, but it reinforces why the most common payment experience is tied to an exam visit.

Article Highlights

• Supply-side anchors often come from clinic listings (box price + box count), not from a single national retail price.
• Cold-ship logistics can add meaningful order-level costs and policy constraints (ship windows, non-return rules) that influence clinic pricing.
• Your pay path decides your receipt: clinic add-on billing vs pharmacy claim can look and feel like different “prices” for the same drug.
• Insurance can still be a barrier when prior authorization timing doesn’t match an exam date.
• To compare options, ask one question first: “Will my office supply RYZUMVI today, or are you sending a prescription to a pharmacy?”

Answers to Common Questions

Is RYZUMVI sold as a multi-dose bottle?

No. It’s supplied as single-patient-use vials (see the FDA label linked at the top of this article).

Why can two people report very different prices?

Because one may pay an in-office dilation reversal add-on (clinic supplied and administered) while another pays a pharmacy claim affected by insurance tiering, deductibles, and possible prior authorization.

What’s the fastest way to estimate a reasonable per-dose floor?

Use the public box anchor divided by 30 vials, then remember cold shipping can raise the delivered per-vial cost before any clinic service markup.